PepsiCo, Inc. vs Zoetis Inc — how do they compare? PepsiCo, Inc. trades at $135.8 (market cap $184.26B), while Zoetis Inc trades at $74.43 (market cap $31.59B). The key difference: PepsiCo, Inc. is far larger — about 5.8× Zoetis Inc's market cap, and PepsiCo, Inc. pays the higher dividend (4.39%). Which is the better fit depends on your goals.
| PEP | ZTS | |
|---|---|---|
Market Cap | $184.26B | $31.59B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $156.76 |
52-Week Low | $134.98 | $71.91 |
Enterprise Value | $226.76B | $38.89B |
Dividend Yield | 4.39% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $135.65, showing minimal daily movement with a slight 0.14% gain. The technical outlook is bearish per moving averages, while fundamentals reflect steady revenue near $94B and strong profitability with a 10.78% net margin. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, alongside ongoing North American recovery efforts ahead of Q1 2026 earnings.
The stock presents a mixed outlook: analyst consensus leans hold (64% of ratings) with a $158.79 price target suggesting upside, but risks include margin pressure from pricing strategies and volatile cash flows. Institutional activity shows mixed signals, with some firms increasing stakes while others reduce holdings, indicating cautious optimism amid competitive and consumer sentiment challenges.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Trailing returns across standard periods
Latest headlines on both assets
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →